These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 4990004)

  • 121. Cyclophosphamide-Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management.
    Dhesi S; Chu MP; Blevins G; Paterson I; Larratt L; Oudit GY; Kim DH
    J Investig Med High Impact Case Rep; 2013; 1(1):2324709613480346. PubMed ID: 26425570
    [TBL] [Abstract][Full Text] [Related]  

  • 122. The hematopoietic system in the context of regenerative medicine.
    Porada CD; Atala AJ; Almeida-Porada G
    Methods; 2016 Apr; 99():44-61. PubMed ID: 26319943
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation.
    Ross D; Jones M; Komanduri K; Levy RB
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1430-8. PubMed ID: 23819914
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Success of allogeneic marrow transplantation for children with severe aplastic anaemia.
    Burroughs LM; Woolfrey AE; Storer BE; Deeg HJ; Flowers ME; Martin PJ; Carpenter PA; Doney K; Appelbaum FR; Sanders JE; Storb R
    Br J Haematol; 2012 Jul; 158(1):120-8. PubMed ID: 22533862
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Hematopoietic-stem-cell-based gene therapy for HIV disease.
    Kiem HP; Jerome KR; Deeks SG; McCune JM
    Cell Stem Cell; 2012 Feb; 10(2):137-47. PubMed ID: 22305563
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase.
    Al-Hashmi S; Boels PJ; Zadjali F; Sadeghi B; Sällström J; Hultenby K; Hassan Z; Arner A; Hassan M
    PLoS One; 2012; 7(1):e30897. PubMed ID: 22303468
    [TBL] [Abstract][Full Text] [Related]  

  • 127. HLA-matched related donor hematopoietic cell transplantation in 43 patients with Fanconi anemia conditioned with 60 mg/kg of cyclophosphamide.
    Bonfim CM; de Medeiros CR; Bitencourt MA; Zanis-Neto J; Funke VA; Setubal DC; Ruiz J; Sanders JE; Flowers ME; Kiem HP; Storb R; Pasquini R
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1455-60. PubMed ID: 18022575
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Cyclophosphamide cardiotoxicity.
    von Bernuth G; Adam D; Hofstetter R; Lang D; Mohr W; Kohne E; Niethammer D
    Eur J Pediatr; 1980 Jun; 134(1):87-90. PubMed ID: 6997053
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Bone marrow transplantation in a patient with drug-induced aplastic anemia.
    Banerjee TK; Band PR; Pabst H; Goldsand G; Armstrong WD; Brown J; Hill JR; Dossetor JB
    Can Med Assoc J; 1972 Sep; 107(5):409-13. PubMed ID: 4403793
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Myocardial diseases of animals.
    Van Vleet JF; Ferrans VJ
    Am J Pathol; 1986 Jul; 124(1):98-178. PubMed ID: 3524254
    [TBL] [Abstract][Full Text] [Related]  

  • 131. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.
    Peters WP; Stuart A; Klotman M; Gilbert C; Jones RB; Shpall EJ; Gockerman J; Bast RC; Moore JO
    Cancer Chemother Pharmacol; 1989; 23(6):377-83. PubMed ID: 2653660
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.
    Mayumi H; Good RA
    J Exp Med; 1989 Jan; 169(1):213-38. PubMed ID: 2642528
    [TBL] [Abstract][Full Text] [Related]  

  • 133. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients.
    Eder JP; Elias AD; Ayash L; Wheeler CA; Shea TC; Schnipper LE; Frei E; Antman KH
    Cancer Chemother Pharmacol; 1991; 29(1):61-5. PubMed ID: 1742850
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Myocardial toxicity of high-dose cyclophosphamide in rabbits treated with daunorubicin.
    Isberg B; Paul C; Jönsson L; Svahn U
    Cancer Chemother Pharmacol; 1991; 28(3):171-80. PubMed ID: 1649704
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Cardiotoxic effects of antitumor agents.
    Ghione M
    Cancer Chemother Pharmacol; 1978; 1(1):24-34. PubMed ID: 373905
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Experimental bone marrow transplantation.
    Thierfelder S
    Blut; 1975 Jan; 30(1):1-18. PubMed ID: 234260
    [No Abstract]   [Full Text] [Related]  

  • 137. Marrow transplantation of aplastic anemia and acute leukemia.
    Thomas ED; Weiden PL
    World J Surg; 1977 Mar; 2(1):197-206. PubMed ID: 17234
    [No Abstract]   [Full Text] [Related]  

  • 138. Cyclophosphamide regimens in rhesus monkey with and without marrow infusion.
    Storb R; Buckner CD; Dillingham LA; Thomas ED
    Cancer Res; 1970 Aug; 30(8):2195-203. PubMed ID: 4990004
    [No Abstract]   [Full Text] [Related]  

  • 139. [Effect of rubomycin C on the blood system in experimental conditions].
    Gol'dberg DI; Kraìushkina NP; Antipov IG
    Antibiotiki; 1971 Mar; 16(3):240-3. PubMed ID: 5558685
    [No Abstract]   [Full Text] [Related]  

  • 140. [Impedance effects of interleukin-6 on cyclophosphamide-induced hematopoietic damnification in dogs].
    Yin H; He X; Bao X; Liu X; Yang G
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Aug; 22(4):798-801. PubMed ID: 16156276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.